Validation of a novel cortical biomarker signature for pain
Ended Project Grant Awarded Last action
- Award ID
- R33NS113269
- Recipient
-
University Of Maryland, Baltimore UEI Z9CRZKD42ZT1
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,708,704
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Place of performance
- Baltimore, MD 21201, USA
Award details come from USAspending.gov.
Description
- Abstract
- Chronic pain is a major health burden associated with immense economic and social costs. Predictive biomarkers that can identify individuals at risk of developing severe and persistent pain, which is associated with worse disability and greater reliance on opioids, would promote aggressive, early intervention that could halt the transition to chronic pain. Our team has uncovered evidence of a unique cortical biomarker signature that predicts pain susceptibility (severity and duration). The biomarker signature combines resting state sensorimotor peak alpha frequency (PAF) measured using electroencephalograph (EEG) and corticomotor excitability (CME) measured using transcranial magnetic stimulation (TMS). This PAF/CME biomarker signature could be capable of predicting the severity of pain experienced by an individual minutes to months in the future, as well as the duration of pain (time to recovery). In the R61 phase of the current proposal, we aim to undertake analytical validation of this biomarker in healthy participants using a standardized model of the transition to sustained myofascial temporomandibular pain (masseter intramuscular injection of nerve growth factor, n=150). We will record PAF/CME at multiple time points before and during the development of pain and use online diaries and in-laboratory assessments of pain, sleep, stress, and other psychosocial variables. Specifically, we will test if the biomarker signature predicts an individual's pain sensitivity (high- or low-pain sensitive) with at least 75% accuracy. We will also test whether the biomarker signature predicts pain severity (on a 0-10 scale) and pain duration (number of days until pain resolves). We will use multiple statistical approaches to optimize and test the performance of the predictive biomarker. In the R33 phase we then aim to perform initial clinical validation to determine whether the optimized PAF/CME biomarker signature predicts pain severity and duration in patients with new onset myofascial temporomandibular disorder (TMD; n=30). We expect our work to result in the delivery of a candidate biomarker signature ready for advanced prospective clinical validation studies.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $854,352 | |
| Original award | $854,352 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Western Ontario | $191,678 |
Quick answers
Who received award R33NS113269?
R33NS113269 was awarded to University Of Maryland, Baltimore by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on August 1, 2019.
How much is award R33NS113269 worth?
$1,708,704 has been obligated on R33NS113269.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award